Market Waking Up to Abbvie's (ABBV) Strong Pipeline - Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Goldman Sachs Raises PT on Abbvie (ABBV) to $52
April 29, 2013 10:45 AM EDTGoldman Sachs today maintained a Buy rating on Abbvie (NYSE: ABBV) and raised its price target to $52.00 (from $45.00). Analyst Jami Rubin said he had greater confidence in Humira growth and in Abbvie's pipeline.
"We estimate that in a best case... More
Abbvie, Inc. (ABBV) Tops Q1 EPS by 1c; Reaffirms Outlook
April 26, 2013 7:52 AM EDT(Updated - April 26, 2013 7:59 AM EDT)
AbbVie (NYSE: ABBV) reported Q1 EPS of $0.68, $0.01 better than the analyst estimate of $0.67. Revenue for the quarter came in at $4.33 billion, versus $4.17 billion reported last year.
On an operational basis, sales increased 5.1 percent, excluding a 1.4 percent unfavorable impact from foreign exchange rate... More
